Literature DB >> 28944311

Integrating genomic information and signaling dynamics for efficient cancer therapy.

Jacob Stewart-Ornstein1, Galit Lahav1.   

Abstract

The field of cancer systems biology has made great strides in understanding oncogenic pathway signaling and enumerating mutations involved in oncogenesis. However, application of these datasets to patient stratification, and to the design of personalized therapy, is in its infancy. We review BRAF and BRCA mutant targeted therapy, where patient stratification has had critical, albeit mixed success. We contrast the work on genomic targeted therapy with orthogonal studies on the dynamics of signaling pathways for designing optimal treatment schedules. We suggest that an integrated approach, combining genomic data and the dynamics of signaling pathways, is required for developing pathway specific computational models and for systematic deployment of targeted combination regimes. The field of cancer systems biology has made great strides in understanding oncogenic pathway signaling and enumerating mutations involved in oncogenesis. However, application of the existing approaches and datasets to patient stratification, and to the design of personalized therapy, is in its infancy. Here we discuss an integrated approach combining genomic data and the dynamics of signaling pathway to develop pathway specific computational models and the systematic deployment of targeted combination regimes. We review recent studies and existing datasets in the field of cancer systems biology and highlight potentially fruitful synergies between the different strands of this discipline.

Entities:  

Year:  2016        PMID: 28944311      PMCID: PMC5608455          DOI: 10.1016/j.coisb.2016.12.013

Source DB:  PubMed          Journal:  Curr Opin Syst Biol        ISSN: 2452-3100


  45 in total

1.  Radiotherapy in breast cancer. I. The dose-time relationship theoretical considerations.

Authors:  L COHEN
Journal:  Br J Radiol       Date:  1952-12       Impact factor: 3.039

Review 2.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

3.  Optimal control analysis in the chemotherapy of IgG multiple myeloma.

Authors:  G W Swan; T L Vincent
Journal:  Bull Math Biol       Date:  1977       Impact factor: 1.758

4.  Cellular control systems and radiosensitivity.

Authors:  J S Orr; C S Hope; J Laurie; J M Stark
Journal:  Nature       Date:  1966-05-14       Impact factor: 49.962

5.  Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.

Authors:  Jasmine Foo; Juliann Chmielecki; William Pao; Franziska Michor
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

6.  Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Authors:  Douglas B Johnson; Keith T Flaherty; Jeffrey S Weber; Jeffrey R Infante; Kevin B Kim; Richard F Kefford; Omid Hamid; Lynn Schuchter; Jonathan Cebon; William H Sharfman; Robert R McWilliams; Mario Sznol; Donald P Lawrence; Geoffrey T Gibney; Howard A Burris; Gerald S Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Kiran Patel; Nageatte Ibrahim; Peng Sun; Shonda Little; Elizabeth Cunningham; Jeffrey A Sosman; Adil Daud; Rene Gonzalez
Journal:  J Clin Oncol       Date:  2014-10-06       Impact factor: 44.544

7.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Authors:  J Ross Chapman; Inger Brandsma; Guotai Xu; Jingsong Yuan; Martin Mistrik; Peter Bouwman; Jirina Bartkova; Ewa Gogola; Daniël Warmerdam; Marco Barazas; Janneke E Jaspers; Kenji Watanabe; Mark Pieterse; Ariena Kersbergen; Wendy Sol; Patrick H N Celie; Philip C Schouten; Bram van den Broek; Ahmed Salman; Marja Nieuwland; Iris de Rink; Jorma de Ronde; Kees Jalink; Simon J Boulton; Junjie Chen; Dik C van Gent; Jiri Bartek; Jos Jonkers; Piet Borst; Sven Rottenberg
Journal:  Nature       Date:  2015-03-23       Impact factor: 49.962

8.  High-resolution sequencing and modeling identifies distinct dynamic RNA regulatory strategies.

Authors:  Michal Rabani; Raktima Raychowdhury; Marko Jovanovic; Michael Rooney; Deborah J Stumpo; Andrea Pauli; Nir Hacohen; Alexander F Schier; Perry J Blackshear; Nir Friedman; Ido Amit; Aviv Regev
Journal:  Cell       Date:  2014-12-11       Impact factor: 41.582

9.  Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis.

Authors:  Suzanne Gaudet; Sabrina L Spencer; William W Chen; Peter K Sorger
Journal:  PLoS Comput Biol       Date:  2012-04-26       Impact factor: 4.475

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.